Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Repligen (RGEN) reports strong 2022 performance, eyes growth amid challenges

Repligen anticipates a challenging yet optimistic year in 2023, with revenue guidance of $760-800 million and adjusted EPS of $2.61-2.69 per fully diluted share. The company remains focused on organic growth, innovation, and strategic acquisitions to navigate industry headwinds.

Repligen reports Q1 revenue growth, eyes China rebound and new products

Repligen's Q1 2023 performance saw revenue growth but overall revenues declined due to reduced COVID-related demand.
Despite challenges in China and revised guidance, strategic investments and confidence in future growth opportunities remain strong.
The company is focused on new product launches, pricing resilience, and addressing challenges to drive growth and margin improvement.

Repligen faces revenue decline and margin pressure, eyes growth strategies

Repligen faces challenges in revenue decline and margin compression but is focusing on cost control and new product launches for growth.
Diversified revenue streams and positive developments in orders and integration provide a foundation for future opportunities.
Market dynamics and pharma spend challenges pose uncertainties, but the company remains optimistic about growth prospects.
Visibility improvements, margin recovery expectations, and pricing strategies are key focus areas for future profitability.

Repligen sees recovery in Q3 amidst industry challenges and restructuring

Repligen's Q3 2023 showed signs of recovery amidst industry challenges, with a focus on cost optimization and new product launches. The company incurred restructuring charges to streamline operations and expects improved margins in 2024. Despite revenue declines, opportunities lie in the gene therapy segment and future recovery in China.

Repligen reports Q4 revenue decline but eyes growth in China

Repligen's Q4 2023 showed mixed results with revenue decline but sequential growth. The company is focusing on profitability improvements in 2024 and anticipates growth driven by new modalities and market recovery. Challenges in revenue performance are being addressed, with a strategic focus on key account management and cost containment.

Repligen reports mixed Q1 results, focuses on innovation and growth

Repligen's Q1 2024 performance showed mixed results with revenue declines but positive growth in key segments. The company maintains its focus on innovation, cost control, and strategic expansion while navigating challenges in profitability. Opportunities lie in market improvements and growth potential in new modalities.

Repligen reports strong Q2 performance, eyes robust growth ahead

Repligen's Q2 2024 earnings call showcased strong performance in pharma and consumables, despite challenges from China and foreign exchange. The company anticipates a return to robust revenue growth in the second half of the year and is optimistic about future growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Repligen Corporation (NASDAQ:RGEN ) Q1 2022 Results Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Sondra Newman - Vice President and Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Dan Arias - Stifel Financial Puneet Souda - SVB Leerink Julia Qin - J.P. Morgan Paul Knight - KeyBanc Capital Markets Justin Lin - William Blair & Company Matthew Hewitt - Craig-Hallum Brandon Couillard - Jefferies LLC Raghuram Selvaraju - H.C.

Repligen Corporation (RGEN) CEO Tony Hunt on Q1 2022 Results - Earnings Call Transcript

A stronger-than-expected earnings report calls months of the stock's weakness into question.

Why Repligen Is Up More Than 10% Today

Repligen (RGEN) delivered earnings and revenue surprises of 27.78% and 12.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Beats Q1 Earnings and Revenue Estimates

—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency

Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

Management has executed its strategy well, but a potential risk is looming.

2 Reasons to Buy Repligen, and 1 Reason to Sell

Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT

Repligen to Report First Quarter 2022 Financial Results

908 Devices

BOSTON--(BUSINESS WIRE)--908 Devices has appointed Tony J. Hunt, President and CEO of Repligen Corporation to serve on its Board of Directors effective immediately.

908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

Repligen (RGEN) CEO, Tony Hunt on Q4 2021 Results - Earnings Call Transcript

Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Tops Q4 Earnings and Revenue Estimates

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%

Repligen Reports Fourth Quarter and Full Year 2021 Financial Results

Exelixis

Ironwood Pharma

Ligand Pharmaceuticals

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More

AVIPure® affinity resins address the market need for high performance and caustic stability AVIPure® affinity resins address the market need for high performance and caustic stability

Repligen Launches AAV Affinity Resins for Gene Therapy Purification

WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 11th Annual SVB Leerink Healthcare Conference being held Feb. 14-18, 2022.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, Feb. 18, at 3:00 p.m. EST.

Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST

Repligen to Report Fourth Quarter and Full Year 2021 Financial Results

Dynavax Technologies

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.

4 Top Biotech Stocks to Gain Amid Industry Challenges

Repligen (RGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 16.5% in 4 Weeks, Here's Why Repligen (RGEN) Looks Ripe for a Turnaround

WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40th Annual J.P. Morgan Healthcare conference being held January 10-13.  Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST.

Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference

BeiGene

Sarepta Therapeutics

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

3 Biotech Stocks Worth Adding to Your Portfolio Next Year

Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Repligen (RGEN) Upgraded to Strong Buy: Here's Why

Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

Sets Baseline and Provides SASB, GRI Core and SDG Disclosures Sets Baseline and Provides SASB, GRI Core and SDG Disclosures

Repligen Releases Inaugural Sustainability Report

Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021.

Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up

Repligen Corporation (RGEN) CEO Anthony Hunt on Q3 2021 Results - Earnings Call Transcript

Repligen (RGEN) delivered earnings and revenue surprises of 21.88% and 8.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Repligen Stock (RGEN)